What changed: Ampullary cancer (ampulla of Vater)
Every dated change on the records linked to Ampullary cancer (ampulla of Vater), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Guideline1Milestone5This record1
September 2026 · 1
2022 · 1
2012 · 2
- 2012GuidelineAmpullary cancer (ampulla of Vater)Guideline NCCN Guidelines: Ampullary Adenocarcinoma; ESPAC-3 (JAMA 2012): Adjuvant
Six months of chemotherapy chosen by subtype: oxaliplatin-fluoropyrimidine (FOLFOX or CAPOX) for intestinal-type; gemcitabine-based or modified FOLFIRINOX for pancreatobiliary-type; evidence is from ESPAC-3 periampullary and retrospective series. (NCCN Category 2A)
- 2012MilestoneGemcitabineESPAC-3 periampullary
Adjuvant chemotherapy after resection of periampullary cancer; survival benefit in adjusted analysis.